GE Healthcare last week at SNM in Salt Lake City presented interim phase 2 study results of fluciclatide, in collaboration with the National Cancer Institute (NCI), part of the National Institutes of Health. Fluciclatide is an integrin-targeted radiopharmaceutical under development for oncology PET imaging.
Esther Mena, MD, an associate investigator at the NCI, presented preliminary data on the uptake and retention properties of fluciclatide in solid tumors.
This phase 2 study is part of a larger multi-site clinical program being conducted in the U.S., Europe, India and Korea, GE said. The goal of the program is to detect and measure integrin expression in patients with various solid tumor types, including melanoma and renal cell carcinoma.
Mena presented preliminary data from 10 patients with solid tumors not previously imaged with fluciclatide. PET/CT imaging of each patient's target lesion was performed for 60 minutes followed by a static whole-body PET/CT scan. The biodistribution of fluciclatide permitted visual analysis of the target lesion as a means to demonstrate variable solid tumor uptake and retention, sometimes with heterogeneous distribution within the tumor.
They also examined the mean and maximum tumor and blood pool standardized uptake values (SUVmax/mean) in the trial.